Artrya Limited · ASX:AYA
Artrya — Bell Potter Healthcare Conference 2025
14 slides from Artrya's conference presentation, Nov 20, 2025
Slide 1: Coronary Artery Disease. We see you.
Coronary Artery Disease. We see you. Bell Potter Healthcare Conference 2025 PERTH, Australia, 20 November 2025: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and m
Slide 2: Corporate and investor contacts
John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artrya.com For personal use only Artrya Limited I ABN 624 005 741 I 1257 Hay Street, West
Slide 3: Bell Potter Healthcare Conference Company Presentation
For personal use only (ASX: AYA) Bell Potter Healthcare Conference Company Presentation 20 November 2025 [ Reshaping the Future of [ Heart Care Not for Release to U.S. wire services or distribution in the United States
Slide 4: Important Notice
Important Notice IMPORTANT NOTICE AND DISCLAIMER The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does These presentation
Slide 5: Artrya at a Glance – an attractive market and model
Artrya at a Glance – an attractive market and model Salix® is the only real-time, point of care platform globally delivering end-to-end CCTA assessment For personal use only Attractive Market Commercial Momentum Differentiated Product • (ASX: AYA) - ~AU$550m market cap • Unified CCTA Reporting Platf
Slide 6: Current methods for diagnosing coronary artery disease are outdated
Current methods for diagnosing coronary artery disease are outdated A point of care solution for rapidly diagnosing high risk plaque is a holy grail for clinicians For personal use only Ineffective Avoidable Old methods ineffective in detecting high- 55% of invasive procedures are risk plaque1 unnec
Slide 7: Salix provides streamlined, real-time patient assessment
Salix® provides streamlined, real-time patient assessment Clear clinical insights into actionable decisions in minutes Point of care enabling real-time analysis – For personal use only without humans CCTA an alysis in under 10 mins without human intervention. Detailed Plaque and Flow Analysis Real-t
Slide 8: From off-site workflows to 10-minute decision
From off-site workflows to 10-minute decision Salix® fits directly into the existing clinical workflow; no uploads, no portals, no off-site vendors For personal use only Onsite - Manual Assessment Workstation Review & Currently Report vendors Prepare Clinician Current • Inefficient Finalizes Report
Slide 9: Coronary artery disease is a large and growing health challenge
Coronary artery disease is a large and growing health challenge Cardiovascular Disease Costs will Exceed $1 Trillion by 2035 - American Heart Association4 12.6 million For personal use only CCTA scans (RoW)2 US$4.4 billion* Serviceable Addressable Market (US) 6.2% YOY 4.4 Projected growth in Cardiac
Slide 10: Salix is a single platform solution built to scale
Salix® is a single platform solution built to scale Modular software powering complete, scalable CCTA analysis for coronary artery disease. Increasing clinical utility & For personal use only revenue opportunity Salix® Coronary Flow Module Final validation stage – Expected FDA clearance 1Q 2026 US$1
Slide 11: Salix platform successfully launched in the U.S.
Salix® platform successfully launched in the U.S. Tanner Health collaboration partnership to validate and integrate For personal use only Integrated and Live from July 2025 Next U.S. launch partners ► 5-year Commercial Agreement – US$0.6M ► Cone Health and Northeast Georgia Health System have been k
Slide 12: Flagship Novel Plaque Study – SAPPHIRE
Flagship Novel Plaque Study – SAPPHIRE Salix-based Analysis of Plaque to identify Patients at Higher Risk of Events The SAPPHIRE study will validate the novel Salix plaque analysis to identify patients at risk of heart attack and improve treatment. For personal use only Clinical and Commercial Benef
Slide 13: Key Takeaways
Key Takeaways Salix® has moved from R&D to commercial use, and a structured pathway for U.S. expansion. 1 For personal use only Commercialisation activities and platform now scaling. 2 Large growing market in the U.S. with established reimbursement codes 3 Salix® platform live in the U.S. – generati
Slide 14: Corporate and investor enquiries
For personal use only www.artrya.com Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artr